Fox Run Management L.L.C. Has $1.29 Million Holdings in Vaxcyte, Inc. $PCVX

Key Points

• Fox Run Management L.L.C. increased its stake in Vaxcyte, Inc. by 758.1%, owning 34,228 shares valued at approximately $1.29 million by the end of the first quarter.
• Vaxcyte has a market capitalization of $4.08 billion, with shares currently trading at $31.43, down 0.4%.
• Analysts have a bullish outlook on Vaxcyte, with an average price target of $136.50 and most rating the stock as a "buy."

Fox Run Management L.L.C. lifted its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 758.1% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 34,228 shares of the company's stock after buying an additional 30,239 shares during the period. Fox Run Management L.L.C.'s holdings in Vaxcyte were worth $1,292,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of PCVX. Parallel Advisors LLC grew its position in Vaxcyte by 203.6% in the first quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock valued at $61,000 after acquiring an additional 1,071 shares during the last quarter. IFP Advisors Inc boosted its stake in shares of Vaxcyte by 376.4% in the 1st quarter. IFP Advisors Inc now owns 1,653 shares of the company's stock valued at $62,000 after purchasing an additional 1,306 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Vaxcyte in the 4th quarter valued at approximately $214,000. Nisa Investment Advisors LLC grew its holdings in shares of Vaxcyte by 10.9% during the 1st quarter. Nisa Investment Advisors LLC now owns 2,977 shares of the company's stock valued at $112,000 after purchasing an additional 293 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in Vaxcyte during the 4th quarter worth approximately $248,000. 96.78% of the stock is currently owned by institutional investors.

Vaxcyte Stock Performance

Shares of NASDAQ:PCVX traded down $0.47 during mid-day trading on Wednesday, reaching $31.26. 1,151,561 shares of the company's stock were exchanged, compared to its average volume of 1,334,744. Vaxcyte, Inc. has a twelve month low of $27.66 and a twelve month high of $121.06. The firm has a market capitalization of $4.06 billion, a price-to-earnings ratio of -7.61 and a beta of 1.21. The business's fifty day moving average price is $33.74 and its 200-day moving average price is $45.46.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($1.22) earnings per share for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.10). During the same quarter last year, the business posted ($1.10) earnings per share. Analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on PCVX. Cowen restated a "buy" rating on shares of Vaxcyte in a research report on Thursday, August 7th. Cantor Fitzgerald initiated coverage on Vaxcyte in a research note on Tuesday, April 22nd. They issued an "overweight" rating for the company. One research analyst has rated the stock with a Strong Buy rating and ten have issued a Buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $136.50.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.